Last reviewed · How we verify

RSD1235 — Competitive Intelligence Brief

RSD1235 (RSD1235) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium channel opener. Area: Cardiovascular.

phase 3 Potassium channel opener ATP-sensitive potassium channels (KATP) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

RSD1235 (RSD1235) — Astellas Pharma Inc. RSD1235 is a potassium channel opener that suppresses atrial fibrillation by prolonging atrial refractoriness and reducing atrial conduction velocity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RSD1235 TARGET RSD1235 Astellas Pharma Inc phase 3 Potassium channel opener ATP-sensitive potassium channels (KATP)
Rogaine minoxidil Generic (originally Upjohn/Pfizer) marketed Vasodilator (potassium channel opener), Hair growth stimulant ATP-sensitive inward rectifier potassium channel 1, Sulfonylurea receptor 2, Kir6.2 1988-08-18
Minoxidil 5 % Topical Spray Minoxidil 5 % Topical Spray Sheikh Zayed Federal Postgraduate Medical Institute marketed Potassium channel opener / Topical hair growth stimulant ATP-sensitive potassium channels (KATP)
KAD-1229 KAD-1229 Kissei Pharmaceutical Co., Ltd. marketed Potassium channel opener ATP-sensitive potassium channel (KATP)
Ezogabine/Retigabine IR Ezogabine/Retigabine IR GlaxoSmithKline marketed Potassium channel opener Kv7 (KCNQ) voltage-gated potassium channels
minoxidil 5% solution minoxidil 5% solution Allergan marketed Potassium channel opener ATP-sensitive potassium channels
ezogabine/retigabine ezogabine/retigabine GlaxoSmithKline marketed Potassium channel opener; anticonvulsant KCNQ potassium channels (Kv7)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium channel opener class)

  1. Kissei Pharmaceutical Co., Ltd. · 2 drugs in this class
  2. Astellas Pharma Inc · 1 drug in this class
  3. Cardurion Pharmaceuticals, Inc. · 1 drug in this class
  4. Dr. dr. Lili Legiawati, SpKK(K) · 1 drug in this class
  5. Eurofarma Laboratorios S.A. · 1 drug in this class
  6. GlaxoSmithKline · 1 drug in this class
  7. Allergan · 1 drug in this class
  8. Triple Hair Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RSD1235 — Competitive Intelligence Brief. https://druglandscape.com/ci/rsd1235. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: